Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin

Masahiro Ohira,1 Takashi Yamaguchi,1 Atsuhito Saiki,1 Noriko Ban,1 Hidetoshi Kawana,1 Ayako Nagumo,1 Takeyoshi Murano,2 Kohji Shirai,3 Ichiro Tatsuno1 1Center for Diabetes, Endocrinology and Metabolism, 2Department of Clinical Laboratory Medicine, 3Department of Vascular Function, Sakura H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagumo A, Murano T, Shirai K, Tatsuno I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5087744065b04a65bdf3fe0c8abbf9a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5087744065b04a65bdf3fe0c8abbf9a1
record_format	dspace
spelling	oai:doaj.org-article:5087744065b04a65bdf3fe0c8abbf9a12021-12-02T02:45:35ZPioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin1178-7007https://doaj.org/article/5087744065b04a65bdf3fe0c8abbf9a12014-07-01T00:00:00Zhttp://www.dovepress.com/pioglitazone-improves-the-cardio-ankle-vascular-index-in-patients-with-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007 Masahiro Ohira,1 Takashi Yamaguchi,1 Atsuhito Saiki,1 Noriko Ban,1 Hidetoshi Kawana,1 Ayako Nagumo,1 Takeyoshi Murano,2 Kohji Shirai,3 Ichiro Tatsuno1 1Center for Diabetes, Endocrinology and Metabolism, 2Department of Clinical Laboratory Medicine, 3Department of Vascular Function, Sakura Hospital, Toho University Medical Center, Chiba, Japan Background: Type 2 diabetes is known to be associated with elevated cardiovascular mortality. Pioglitazone improves blood pressure (BP) and pulse wave velocity (PWV), which is an arterial stiffness parameter. Arterial stiffness is closely associated with cardiovascular disease. However, PWV is correlated with BP. The cardio-ankle vascular index (CAVI) reflects arterial stiffness independent of BP. Pioglitazone improves PWV but reduces blood pressure. The aim of this study was to re-evaluate the effect of pioglitazone on arterial stiffness with CAVI. Methods: Sixty patients with type 2 diabetes mellitus and already on 500 mg/day of metformin received add-on therapy of pioglitazone 15 mg/day or glimepiride 1 mg/day for 6 months, during which time changes in their metabolic parameters and CAVI were observed. Results: After 6 months of treatment, both pioglitazone (n=30) and glimepiride (n=30) improved fasting blood glucose and glycated hemoglobin. The changes in fasting blood glucose and glycated hemoglobin between the two groups were greater in the pioglitazone group. Systolic and diastolic BP was decreased in both groups, with no significant between-group differences. Only pioglitazone increased serum adiponectin levels, and the change in adiponectin between the pioglitazone and glimepiride groups was significantly different. CAVI was decreased significantly by pioglitazone but remained unchanged after treatment with glimepiride. The change in CAVI between the two groups was significantly different. Conclusion: These results suggest that pioglitazone improves CAVI, a BP-independent arterial stiffness parameter, in patients with type 2 diabetes mellitus treated with metformin. Keywords: biguanide, thiazolidinediones, sulfonylurea, blood pressure, cardiovascular disease, arterial stiffnessOhira MYamaguchi TSaiki ABan NKawana HNagumo AMurano TShirai KTatsuno IDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2014, Iss default, Pp 313-319 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Ohira M Yamaguchi T Saiki A Ban N Kawana H Nagumo A Murano T Shirai K Tatsuno I Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
description	Masahiro Ohira,1 Takashi Yamaguchi,1 Atsuhito Saiki,1 Noriko Ban,1 Hidetoshi Kawana,1 Ayako Nagumo,1 Takeyoshi Murano,2 Kohji Shirai,3 Ichiro Tatsuno1 1Center for Diabetes, Endocrinology and Metabolism, 2Department of Clinical Laboratory Medicine, 3Department of Vascular Function, Sakura Hospital, Toho University Medical Center, Chiba, Japan Background: Type 2 diabetes is known to be associated with elevated cardiovascular mortality. Pioglitazone improves blood pressure (BP) and pulse wave velocity (PWV), which is an arterial stiffness parameter. Arterial stiffness is closely associated with cardiovascular disease. However, PWV is correlated with BP. The cardio-ankle vascular index (CAVI) reflects arterial stiffness independent of BP. Pioglitazone improves PWV but reduces blood pressure. The aim of this study was to re-evaluate the effect of pioglitazone on arterial stiffness with CAVI. Methods: Sixty patients with type 2 diabetes mellitus and already on 500 mg/day of metformin received add-on therapy of pioglitazone 15 mg/day or glimepiride 1 mg/day for 6 months, during which time changes in their metabolic parameters and CAVI were observed. Results: After 6 months of treatment, both pioglitazone (n=30) and glimepiride (n=30) improved fasting blood glucose and glycated hemoglobin. The changes in fasting blood glucose and glycated hemoglobin between the two groups were greater in the pioglitazone group. Systolic and diastolic BP was decreased in both groups, with no significant between-group differences. Only pioglitazone increased serum adiponectin levels, and the change in adiponectin between the pioglitazone and glimepiride groups was significantly different. CAVI was decreased significantly by pioglitazone but remained unchanged after treatment with glimepiride. The change in CAVI between the two groups was significantly different. Conclusion: These results suggest that pioglitazone improves CAVI, a BP-independent arterial stiffness parameter, in patients with type 2 diabetes mellitus treated with metformin. Keywords: biguanide, thiazolidinediones, sulfonylurea, blood pressure, cardiovascular disease, arterial stiffness
format	article
author	Ohira M Yamaguchi T Saiki A Ban N Kawana H Nagumo A Murano T Shirai K Tatsuno I
author_facet	Ohira M Yamaguchi T Saiki A Ban N Kawana H Nagumo A Murano T Shirai K Tatsuno I
author_sort	Ohira M
title	Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
title_short	Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
title_full	Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
title_fullStr	Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
title_full_unstemmed	Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
title_sort	pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/5087744065b04a65bdf3fe0c8abbf9a1
work_keys_str_mv	AT ohiram pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT yamaguchit pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT saikia pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT bann pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT kawanah pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT nagumoa pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT muranot pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT shiraik pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin AT tatsunoi pioglitazoneimprovesthecardioanklevascularindexinpatientswithtype2diabetesmellitustreatedwithmetformin
_version_	1718402159576350720

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin

Ejemplares similares